FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2993601601> ?p ?o ?g. }

• W2993601601 endingPage "175" @default.
• W2993601601 startingPage "159" @default.
• W2993601601 abstract "•First large prospective study of fundus autofluorescence in a cohort of molecularly confirmed children with STGD1.•Fundus autofluorescence is a robust structural outcome measure in children with Stargardt disease.•A high rate of progression was observed in childhood-onset disease, making this subtype of STGD1 ideally suited to be considered for prioritization in clinical trials. PurposeTo determine the reliability and repeatability of quantitative evaluation of areas of decreased autofluorescence (DAF) from fundus autofluorescence (FAF) images and track disease progression in children with Stargardt disease (STGD1), and to investigate clinical and genotype correlations, disease symmetry, and intrafamilial variability.DesignProspective cohort study.MethodsChildren and adults with molecularly confirmed STGD1 (n = 90) underwent longitudinal FAF imaging with subsequent semiautomated measurement of the area of DAF and calculation of the annual rate of progression. The age of disease onset was recorded for all subjects, as well as the electroretinography (ERG) group at baseline (n = 86). Patients were grouped for analysis based on the age at baseline and age of onset, into children (n = 56), adults with childhood-onset STGD1 (n = 15), and adults with adult-onset (n = 19). Fifty FAF images were selected randomly and analyzed by 2 observers to evaluate repeatability and reproducibility. Differences between groups, interocular symmetry, genotype–phenotype correlations, and intrafamilial variability were also investigated both for baseline measurements as well as progression rates. We measured visual acuity, molecular genetics, ERG group, FAF metrics, and their correlations.ResultsThe mean age of onset ± SD was 9.6 ± 3.4 years for childhood-onset (n = 71) and 28.3 ± 7.8 years for adult-onset STGD1 (n = 19). The intra- and interobserver reliability of DAF quantification was excellent (intraclass correlation coefficients 0.995 and 0.987, respectively). DAF area was symmetric between eyes and the mean rate of progression (SD) was 0.69 (0.72), 0.78 (0.48), and 0.40 (0.36) mm2/year for children, adults with childhood-onset, and adults with adult-onset disease, respectively. Patients belonging to a group 3 ERG phenotype (generalized cone and rod dysfunction) had a significantly greater progression rate. Limited intrafamilial variability was observed.ConclusionsThis is the first large prospective study of FAF in a cohort of molecularly confirmed children with STGD1. DAF area quantification was highly reliable and may thereby serve as a robust structural endpoint. A high rate of progression was observed in childhood-onset disease, making this subtype of STGD1 ideally suited to be considered for prioritization in clinical trials. To determine the reliability and repeatability of quantitative evaluation of areas of decreased autofluorescence (DAF) from fundus autofluorescence (FAF) images and track disease progression in children with Stargardt disease (STGD1), and to investigate clinical and genotype correlations, disease symmetry, and intrafamilial variability. Prospective cohort study. Children and adults with molecularly confirmed STGD1 (n = 90) underwent longitudinal FAF imaging with subsequent semiautomated measurement of the area of DAF and calculation of the annual rate of progression. The age of disease onset was recorded for all subjects, as well as the electroretinography (ERG) group at baseline (n = 86). Patients were grouped for analysis based on the age at baseline and age of onset, into children (n = 56), adults with childhood-onset STGD1 (n = 15), and adults with adult-onset (n = 19). Fifty FAF images were selected randomly and analyzed by 2 observers to evaluate repeatability and reproducibility. Differences between groups, interocular symmetry, genotype–phenotype correlations, and intrafamilial variability were also investigated both for baseline measurements as well as progression rates. We measured visual acuity, molecular genetics, ERG group, FAF metrics, and their correlations. The mean age of onset ± SD was 9.6 ± 3.4 years for childhood-onset (n = 71) and 28.3 ± 7.8 years for adult-onset STGD1 (n = 19). The intra- and interobserver reliability of DAF quantification was excellent (intraclass correlation coefficients 0.995 and 0.987, respectively). DAF area was symmetric between eyes and the mean rate of progression (SD) was 0.69 (0.72), 0.78 (0.48), and 0.40 (0.36) mm2/year for children, adults with childhood-onset, and adults with adult-onset disease, respectively. Patients belonging to a group 3 ERG phenotype (generalized cone and rod dysfunction) had a significantly greater progression rate. Limited intrafamilial variability was observed. This is the first large prospective study of FAF in a cohort of molecularly confirmed children with STGD1. DAF area quantification was highly reliable and may thereby serve as a robust structural endpoint. A high rate of progression was observed in childhood-onset disease, making this subtype of STGD1 ideally suited to be considered for prioritization in clinical trials." @default.
• W2993601601 created "2019-12-13" @default.
• W2993601601 creator A5014985557 @default.
• W2993601601 creator A5015985989 @default.
• W2993601601 creator A5017981199 @default.
• W2993601601 creator A5018139814 @default.
• W2993601601 creator A5053090602 @default.
• W2993601601 creator A5070277537 @default.
• W2993601601 creator A5072330187 @default.
• W2993601601 creator A5076678260 @default.
• W2993601601 creator A5081448282 @default.
• W2993601601 date "2020-03-01" @default.
• W2993601601 modified "2023-10-18" @default.
• W2993601601 title "Prospective Cohort Study of Childhood-Onset Stargardt Disease: Fundus Autofluorescence Imaging, Progression, Comparison with Adult-Onset Disease, and Disease Symmetry" @default.
• W2993601601 cites W162823058 @default.
• W2993601601 cites W1721144965 @default.
• W2993601601 cites W173109499 @default.
• W2993601601 cites W1970134158 @default.
• W2993601601 cites W1982740394 @default.
• W2993601601 cites W1985683301 @default.
• W2993601601 cites W1990068376 @default.
• W2993601601 cites W1990208195 @default.
• W2993601601 cites W1991544676 @default.
• W2993601601 cites W1994172606 @default.
• W2993601601 cites W2015795623 @default.
• W2993601601 cites W2015944929 @default.
• W2993601601 cites W2018253988 @default.
• W2993601601 cites W2019329416 @default.
• W2993601601 cites W2019731198 @default.
• W2993601601 cites W2023453045 @default.
• W2993601601 cites W2027567557 @default.
• W2993601601 cites W2044374882 @default.
• W2993601601 cites W2046608494 @default.
• W2993601601 cites W2055642010 @default.
• W2993601601 cites W2060448170 @default.
• W2993601601 cites W2077276946 @default.
• W2993601601 cites W2083848488 @default.
• W2993601601 cites W2089333636 @default.
• W2993601601 cites W2090091834 @default.
• W2993601601 cites W2091540776 @default.
• W2993601601 cites W2102445483 @default.
• W2993601601 cites W2123330867 @default.
• W2993601601 cites W2124851578 @default.
• W2993601601 cites W2144184852 @default.
• W2993601601 cites W2147461641 @default.
• W2993601601 cites W2147560227 @default.
• W2993601601 cites W2171636319 @default.
• W2993601601 cites W2220452512 @default.
• W2993601601 cites W2277641745 @default.
• W2993601601 cites W2305359735 @default.
• W2993601601 cites W2398718305 @default.
• W2993601601 cites W2409247196 @default.
• W2993601601 cites W2473036438 @default.
• W2993601601 cites W2505357900 @default.
• W2993601601 cites W2517104928 @default.
• W2993601601 cites W2527764618 @default.
• W2993601601 cites W2555596972 @default.
• W2993601601 cites W2618137579 @default.
• W2993601601 cites W2740108762 @default.
• W2993601601 cites W2765837584 @default.
• W2993601601 cites W2767387764 @default.
• W2993601601 cites W2782093133 @default.
• W2993601601 cites W2801624020 @default.
• W2993601601 cites W2808419704 @default.
• W2993601601 cites W2902038842 @default.
• W2993601601 cites W2914298339 @default.
• W2993601601 cites W2919339081 @default.
• W2993601601 cites W73797966 @default.
• W2993601601 doi "https://doi.org/10.1016/j.ajo.2019.11.008" @default.
• W2993601601 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7082771" @default.
• W2993601601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31812472" @default.
• W2993601601 hasPublicationYear "2020" @default.
• W2993601601 type Work @default.
• W2993601601 sameAs 2993601601 @default.
• W2993601601 citedByCount "36" @default.
• W2993601601 countsByYear W29936016012020 @default.
• W2993601601 countsByYear W29936016012021 @default.
• W2993601601 countsByYear W29936016012022 @default.
• W2993601601 countsByYear W29936016012023 @default.
• W2993601601 crossrefType "journal-article" @default.
• W2993601601 hasAuthorship W2993601601A5014985557 @default.
• W2993601601 hasAuthorship W2993601601A5015985989 @default.
• W2993601601 hasAuthorship W2993601601A5017981199 @default.
• W2993601601 hasAuthorship W2993601601A5018139814 @default.
• W2993601601 hasAuthorship W2993601601A5053090602 @default.
• W2993601601 hasAuthorship W2993601601A5070277537 @default.
• W2993601601 hasAuthorship W2993601601A5072330187 @default.
• W2993601601 hasAuthorship W2993601601A5076678260 @default.
• W2993601601 hasAuthorship W2993601601A5081448282 @default.
• W2993601601 hasBestOaLocation W29936016011 @default.
• W2993601601 hasConcept C118487528 @default.
• W2993601601 hasConcept C121332964 @default.
• W2993601601 hasConcept C142724271 @default.
• W2993601601 hasConcept C179687394 @default.
• W2993601601 hasConcept C188816634 @default.
• W2993601601 hasConcept C2776391266 @default.
• W2993601601 hasConcept C2776403814 @default.
• W2993601601 hasConcept C2777767895 @default.

• next